Modeling pharmacodynamic response to the poly(ADP-ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Ji, Jiuping ^a   Kinders, Robert J ^b   Zhang, Yiping ^a   Rubinstein, Larry ^c   Kummar, Shivaani ^c   Parchment, Ralph E ^b   Tomaszewski, Joseph E ^c   Doroshow, James H ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLY(ADENOSINE DIPHOSPHATE RIBOSE); VELIPARIB; 2 ((R) 2 METHYLPYRROLIDIN 2 YL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE; BENZIMIDAZOLE DERIVATIVE; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG MECHANISM; ENZYME POLYMORPHISM; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOASSAY; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ANALYSIS; TUMOR BIOPSY; VALIDATION PROCESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; REPRODUCIBILITY; TUMOR CELL LINE;

BENZIMIDAZOLES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; IMMUNOASSAY; LEUKOCYTES, MONONUCLEAR; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES; REPRODUCIBILITY OF RESULTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053911243     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026152     Document Type: Article

References (21)

1. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, et al. (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27: 2705-2711.
2. Amé JC, Spenlehauer C, de Murcia G, (2004) The PARP superfamily. Bioessays 26: 882-893.
3. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13: 2728-2737.
4. Curtin NJ, (2005) PARP inhibitors for cancer therapy. Expert Rev Mol Med 7: 1-20.
5. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
6. Jagtap P, Szabó C, (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4: 421-440.
7. Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, et al. (2010) Histone γH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 16: 4532-4542.
8. Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, et al. (2008) Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res 14: 6877-6885.
9. Kummar S, Kinders RJ, Rubinstein L, Parchment RE, Murgo AJ, et al. (2007) Compressing drug development timelines in oncology using phase ′0′ trials. Nat Rev Cancer 7: 131-139.
10. 13 DCTD Research Resources: Biomarkers Available: . Accessed 2011 Jul.
11. Rubinstein LV, Steinberg SM, Kummar S, Kinders R, Parchment RE, et al. (2010) The statistics of phase 0 trials. Stat Med 29: 1072-1076.
12. Liu X, Palma J, Kinders R, Shi Y, Donawho C, et al. (2008) An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem 381: 240-247.
13. Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, et al. (2004) Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res 10: 3885-3896.
14. Findlay JW, Smith WC, Lee JW, Nordblom GD, Das I, et al. (2000) Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 21: 1249-1273.
15. Virág L, Szabó C, (2002) The therapeutic potential of poly(ADP-Ribose) polymerase inhibitors. Pharmacol Rev 54: 375-429.
16. Zaremba T, Ketzer P, Cole M, Coulthard S, Plummer ER, et al. (2009) Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br J Cancer 101: 256-262.
17. Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM, (2010) Upregulation of poly (ADP-ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 1: 812-821.
18. Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, et al. (2011) Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochem J 436: 671-679.
19. Kunzmann A, Liu D, Annett K, Malaisé M, Thaa B, et al. (2006) Flow-cytometric assessment of cellular poly(ADP-ribosyl)ation capacity in peripheral blood lymphocytes. Immunity & Ageing 3: 8.
20. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
21. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.